Teva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated

MT Newswires Live

Nov 06, 2024

Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.

Analysts polled by Capital IQ expected $0.66.

Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.

Analysts polled by Capital IQ expected $4.13 billion.

The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.

Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.

Shares of the company were up 3.9% in recent Wednesday premarket activity.

Price: 19.50, Change: +0.73, Percent Change: +3.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481934780"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481934780\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481934780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481934780","market":"nz","top_or_hot":-1,"title":"Teva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.</p><p>Analysts polled by Capital IQ expected $0.66.</p><p>Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.</p><p>Analysts polled by Capital IQ expected $4.13 billion.</p><p>The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.</p><p>Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.</p><p>Shares of the company were up 3.9% in recent Wednesday premarket activity.</p><p>Price: 19.50, Change: +0.73, Percent Change: +3.89</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Q3 Non-GAAP Earnings, Net Revenue Rise; 2024 Outlook Updated\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-06 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.</p><p>Analysts polled by Capital IQ expected $0.66.</p><p>Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.</p><p>Analysts polled by Capital IQ expected $4.13 billion.</p><p>The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.</p><p>Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.</p><p>Shares of the company were up 3.9% in recent Wednesday premarket activity.</p><p>Price: 19.50, Change: +0.73, Percent Change: +3.89</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481934780","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481934780","pubTimestamp":1730897012,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries  reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.Analysts polled by Capital IQ expected $0.66.Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.Analysts polled by Capital IQ expected $4.13 billion.The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.Shares of the company were up 3.9% in recent Wednesday premarket activity.Price: 19.50, Change: +0.73, Percent Change: +3.89","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"梯瓦制药第三季度非公认会计准则盈利、净收入增长；2024年展望更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.Analysts polled by Capital IQ expected $0.66.Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.Analysts polled by Capital IQ expected $4.13 billion.The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.Shares of the company were up 3.9% in recent Wednesday premarket activity.Price: 19.50, Change: +0.73, Percent Change: +3.89","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}